Neoadjuvant therapy gains FDA approval in non-small cell lung cancer

Forde et al.(1) reported on a randomized clinical trial (CheckMate 816) and showed that neoadjuvant therapy with nivolumab plus chemotherapy led to improved event-free survival and pathological complete response rate in patients with resectable non-small cell lung cancer (NSCLC).

Detalles Bibliográficos
Autores principales: Leal, Ticiana A., Ramalingam, Suresh S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Spotlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381414/
https://www.ncbi.nlm.nih.gov/pubmed/35858590
http://dx.doi.org/10.1016/j.xcrm.2022.100691
Descripción
Sumario:Forde et al.(1) reported on a randomized clinical trial (CheckMate 816) and showed that neoadjuvant therapy with nivolumab plus chemotherapy led to improved event-free survival and pathological complete response rate in patients with resectable non-small cell lung cancer (NSCLC).

Ejemplares similares